Biosimilar Humira Settlements Stand Firm In US

Purchasers Had Alleged Anticompetitive Conduct

Settlement agreements reached by Humira biosimilar chasers Amgen, Samsung Bioepis and Sandoz in 2017 and 2018 were challenged in court by adalimumab purchasers, which alleged they formed were a part of a broader scheme to hold up competition to the multi-billion-dollar blockbuster brand in the US. But the biosimilar firms and AbbVie will not have to face the antitrust claims.

Gavel
The court described plaintiffs' theory of antitrust injury as 'not plausible' • Source: Shutterstock

Patent-litigation settlements agreed by biosimilar sponsors Amgen, Samsung Bioepis and Sandoz that played a part in AbbVie maintaining control over the market for Humira (adalimumab) in the US do not amount to violations of antitrust regulations, a US district court has held.

Illinois district judge Manish Shah dismissed both federal and state claims brought by a class of indirect Humira purchasers, including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By 

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By 

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By 

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

More from Products

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By 

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By 

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.